CSIMarket
 

Lite Strategy Inc   (NASDAQ: LITS)

Lite Strategy Inc 's

Competitiveness




 

LITS Sales vs. its Competitors Q3 2026



Comparing the current results to its competitors, Lite Strategy Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.12 %, recorded in the same quarter.

List of LITS Competitors





Revenue Growth Comparisons




Net Income Comparison


Lite Strategy Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 386.65 %

<<  LITS Stock Performance Comparisons


Lite Strategy Inc 's Comment on Competition and Industry Peers


The company's drug candidates face competition from numerous entities, including pharmaceutical and biotechnology companies, universities, and public and private research institutions. Competitors have products or drug candidates at various stages of pre-clinical or clinical development targeting the same therapeutic indications. Some competitors' drug candidates are more advanced and may reach commercialization sooner. Many competitors possess greater capital resources, larger research and development staffs and facilities, and more experience in drug development, regulation, manufacturing, marketing, and commercialization. They also compete in recruiting clinical study sites and patients, securing development and commercialization partners, and licensing technologies that could impact the competitiveness of the company's products.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Lite Strategy Inc




Actinium Pharmaceuticals Inc
Share Performance



-41.62%
One Year



Actinium Pharmaceuticals Inc
Profile

Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.

More about Actinium Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 31.721 mill. $ 35.090 mill. $ 37.853 mill.


Karyopharm Therapeutics Inc
Share Performance



-6.09%
30 Days



Karyopharm Therapeutics Inc
Profile

Karyopharm Therapeutics Inc's business model revolves around developing and commercializing novel therapeutic products to treat various types of cancers and other diseases.

More about Karyopharm Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 45.723 mill. $ 151.118 mill. $ -194.969 mill.


Kronos Bio Inc
Share Performance



+27.91%
30 Days



Kronos Bio Inc
Profile

Kronos Bio Inc's business model focuses on developing therapeutics for the treatment of cancer. They utilize a precision medicine approach to target and inhibit novel transcription factors, which play a critical role in the progression of various types of cancer.

More about Kronos Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 53.510 mill. $ 9.192 mill. $ -64.485 mill.


Madrigal Pharmaceuticals Inc
Share Performance



+8.26%
This Quarter



Madrigal Pharmaceuticals Inc
Profile

Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.

More about Madrigal Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15,629.895 mill. $ 1,132.490 mill. $ -309.437 mill.


Mira Pharmaceuticals Inc
Share Performance



0.00%
30 Days



Mira Pharmaceuticals Inc
Profile

Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.

More about Mira Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 36.070 mill. $ - mill. $ -9.809 mill.

69 more competitors available

Sign in to see all competitors

Sources: Lite Strategy Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lite Strategy Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.